Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma.

The document discusses genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma. It highlights the importance of disrupting the PD1/PDL1 axis in cancer treatment and describes acquired resistance mechanisms, including upregulated PDL1 expression due to a CD274 structural variant. The patient underwent treatment with atezolizumab and experienced disease recurrence, leading to further genomic characterization and subsequent therapy adjustments. The findings suggest potential implications for personalized treatment approaches in various cancers where PDL1 blockade is utilized. [Extracted from the article]